ARS Pharmaceuticals Investors Have Deadline to Lead Lawsuit

Rosen Law Firm, an investor rights law firm, has alerted purchasers of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) securities who bought between March 9, 2026, and June 24, 2026, of a critical October 5, 2026 deadline. The date is for investors to seek to become lead plaintiff in a securities fraud lawsuit.

The lawsuit alleges that ARS Pharmaceuticals made false and misleading statements regarding the expected timeline for expanded insurance coverage for its epinephrine nasal spray, neffy, through CVS Caremark. According to the complaint, the company expressed confidence that coverage would begin July 1, 2026, while allegedly concealing material adverse facts or disseminating misleading information about the actual status of this coverage.

Investors who sustained losses during the class period are encouraged by the firm to consider leading the litigation. Serving as lead plaintiff requires a representative party to act on behalf of other class members. Such plaintiffs may be entitled to compensation without incurring out-of-pocket costs through a contingency fee arrangement.

The class action has already been filed, and the deadline to file a motion to serve as lead plaintiff is October 5, 2026. The firm advises interested investors to contact them for more information. Rosen Law Firm notes that an investor's ability to share in any potential recovery is not dependent on serving as lead plaintiff.